Cure possible for Chronic Myeloid Leukemia (CML) ?
Combination of ruxolitinib with tyrosine kinase inhibitor
Important notice: You must inform your CML doctor or a qualified doctor before using this drug. The material presented here is for information purposes only; it is not a substitute for your physician’s guidance and care.
Ruxolitinib (Jakavi) is a JAK1/JAK2 inhibitor and is used in myelofibrosis and MPNs. Scientists have found that ruxolitinib in combination with tyrosine kinase inhibitors can potentially kill CML stem cells through the STAT5 pathway.
Ruxolitinib (Jakavi) is a JAK1/JAK2 inhibitor and is used in myelofibrosis and MPNs. Scientists have found that ruxolitinib in combination with tyrosine kinase inhibitors can potentially kill CML stem cells through the STAT5 pathway.
CLINICAL TRIALS
Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients
Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD)
Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia
Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL Patients (CoRNea)
Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients
Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD)
Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia
Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL Patients (CoRNea)
ARTICLES
Ruxolitinib/nilotinib cotreatment inhibits leukemia-propagating cells in Philadelphia chromosome-positive ALL
August 30, 2017, Journal of Translational Medicine
A Phase I Study of Ruxolitinib Plus Nilotinib in Chronic Phase CML Patients with Molecular Evidence of Disease
2016, Journal Blood
Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib
October 2, 2015, Journal Blood
JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo
2014, Journal Blood
Janus kinase inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model of Ph+ ALL
June 2014, Journal Blood
Imatinib and ruxolitinib association: first experience in two patients
June 2014, Haematologica
